reports
- Emira Sagaama
- Jean-François Granjon
- Oddo Sustainability Team
- Thomas Zlowodzki
- Emira Sagaama
- Jean-François Granjon
- Oddo Sustainability Team
- Thomas Zlowodzki
- Aurelien Sivignon
- Aurelien Sivignon
DBV Technologies Establishes an At-The-Market (ATM) Program on Nasdaq
DBV Technologies Establishes an At-The-Market (ATM) Program on Nasdaq Châtillon, France, September 5, 2025 DBV Technologies Establishes an At-The-Market (ATM) Program on Nasdaq DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Capital Market: DBVT) (the “Company”), a clinical-stage biopharmaceutical company, today announced that it has filed a prospectus supplement with the U.S. Securities and Exchange Commission (“SEC”) relating to an at-the-market offering (the “ATM Program”). Pursuant to this new financing program, the Company may offer and sell, including with unsolicited ...
DBV Technologies met en place un Programme At-The-Market (ATM) sur le ...
DBV Technologies met en place un Programme At-The-Market (ATM) sur le Nasdaq Châtillon, France, le 5 septembre (22:30 CEST) 2025 DBV Technologies met en place un Programme At-The-Market (ATM) sur le Nasdaq DBV Technologies (Euronext : DBV – ISIN : FR0010417345 – Nasdaq Capital Market : DBVT) (la « Société »), une société biopharmaceutique au stade clinique, a annoncé ce jour l’enregistrement d’un supplément au prospectus (« prospectus supplement ») auprès de la U.S. Securities and Exchange Commission (la « SEC ») aux Etats-Unis dans le cadre de la mise en place d’un programme de fina...
Inventiva to Participate in Upcoming September Investor Conferences
Inventiva to Participate in Upcoming September Investor Conferences Daix (France), New York City (New York, United States), September 4, 2025 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced that the Company’s leadership will participate in the following upcoming investor events: H.C. Wainwright 27th Annual Global Investment ConferenceDate: Tuesday, September 9, 2025Time of the fi...
Inventiva annonce sa participation à plusieurs conférences investisseu...
Inventiva annonce sa participation à plusieurs conférences investisseurs en septembre Daix (France), New York City (New York, Etats-Unis), le 4 septembre 2025 – (Euronext Paris et Nasdaq : ) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement de thérapies orales pour le traitement de la stéatohépatite associée à un dysfonctionnement métabolique (« MASH »), a annoncé aujourd’hui que son équipe de direction participera aux conférences investisseurs suivantes :H.C. Wainwright 27th Annual Global Investment Conference Date : Mardi 9 septembre 2025Heur...
QUADIENT SA: Monthly information on number of shares and voting rights
QUADIENT SA: Monthly information on number of shares and voting rights In accordance with article 223.11 of Autorité des Marchés Financiers’ (French Securities and Investment board) General Regulations Ordinary shares - ISIN: FR0000120560 As at 31 August 2025Total number of shares34,468,912Theoretical total number of voting rights34,468,912Net total number of voting rights33,710,334 For more information, please contact: Anne-Sophie Jugean, Quadient+33 (0)1 45 36 30 24 Or visit our website: Attachment
QUADIENT SA: Information mensuelle relative au nombre total d’actions ...
QUADIENT SA: Information mensuelle relative au nombre total d’actions et de droits de vote Etabli en application de l’article 223.11 du Règlement Général de l’Autorité des Marchés Financiers Catégorie des titres concernés : Actions ordinaires - ISIN : FR0000120560 Au 31 août 2025Nombre total d’actions34 468 912Nombre total de droits de vote théorique34 468 912Nombre de droits de vote net33 710 334 Pour toute information complémentaire vous pouvez contacter : Anne-Sophie Jugean, Quadient+33 (0)1 45 36 30 24 Ou consulter notre site Internet : Pièce jointe ...
DBV Technologies to Participate in the H.C. Wainwright 27th Annual Glo...
DBV Technologies to Participate in the H.C. Wainwright 27th Annual Global Investment Conference Châtillon, France, September 3, 2025 DBV Technologies to Participate in the H.C. Wainwright 27th Annual Global Investment Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a clinical-stage biopharmaceutical company, today announced that Daniel Tassé, Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 27th Annual Global Investment Conference on Tuesday, September 9, 2025, at 11:30am ET, in New York, N...
DBV Technologies participera à la 27e conférence annuelle H.C. Wainwri...
DBV Technologies participera à la 27e conférence annuelle H.C. Wainwright Global Investment Châtillon, France, le 3 septembre (22:30 CEST) 2025 DBV Technologies participera à la 27e conférence annuelle H.C. Wainwright Global Investment DBV Technologies (Euronext : DBV – ISIN : FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP : 23306J309), une société biopharmaceutique au stade clinique a annoncé aujourd'hui que Daniel Tassé, Directeur Général, participera à une discussion « fireside chat » lors de la 27e conférence annuelle H.C. Wainwright Global Investment, le mardi 9 septembre 2025 à ...
Quadient Recognized as a Leader in Accounts Payable Automation by Inde...
Quadient Recognized as a Leader in Accounts Payable Automation by Independent Analyst Firm QKS Group’s SPARK Matrix: Accounts Payable Automation 2025 report names Quadient as a Leader for the third year in a row Quadient (Euronext Paris: QDT), a global intelligent automation platform enabling secure and professional business connections, has been named a Technology Leader in the , an independent market evaluation conducted by QKS Group. This is the third consecutive year Quadient has been positioned as a Leader in the report, which includes a competitive analysis and ranking of leading ac...
Automatisation des comptes fournisseurs : Quadient reconnue comme Lead...
Automatisation des comptes fournisseurs : Quadient reconnue comme Leader par un cabinet d’analystes indépendant Le rapport SPARK Matrix : Accounts Payable Automation 2025 du groupe QKS désigne Quadient comme leader pour la troisième année consécutive Quadient (Euronext Paris : QDT), une plateforme mondiale d’automatisation intelligente facilitant des transactions professionnelles et sécurisées, annonce avoir été désignée Leader Technologique dans le dernier rapport , une évaluation indépendante du cabinet de conseil et d’analyse technologique QKS Group. C’est la troisième année consécutiv...
Nanobiotix to Participate in the H.C. Wainwright 27th Annual Global In...
Nanobiotix to Participate in the H.C. Wainwright 27th Annual Global Investment Conference PARIS and CAMBRIDGE, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering nanoparticle-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announced today that Company management will participate in a fireside chat at following conference: H.C. Wainwright 27th Annual Global Investment ConferenceDate: Tuesday, September 9th, 2025Time: 9:00 am EDT / 3:00 pm...
Nanobiotix participera à la conférence investisseurs annuelle H.C. Wai...
Nanobiotix participera à la conférence investisseurs annuelle H.C. Wainwright global investment PARIS et CAMBRIDGE, Mass., 02 sept. 2025 (GLOBE NEWSWIRE) -- (Euronext : NANO –– NASDAQ : NBTX – la « Société »), société française de biotechnologie en phase de développement clinique avancé, pionnière des approches fondées sur les nanoparticules pour élargir les possibilités de traitement des patients atteints de cancer ou d’autres maladies, annonce aujourd’hui que Nanobiotix participera à une discussion (« fireside chat ») à la conférence suivante : Conférence H.C. Wainwright 27th Annual G...
Évolutions au sein du Comité exécutif
Évolutions au sein du Comité exécutif Changes within the Executive Committee Villepinte, August 29, 2025, 5.45 p.m.: Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging, is today announcing two changes within its Executive Committee, the appointment of Éric Kummer as Senior Vice-President of Technical Operations and a change in the management of the Commercial Operations division. Éric Kummer appointed SVP of Technical Operations Éric Kummer will join the Group on October 14, 2025 as Senior Vice-Preside...
- Guy Sips
- Jacob Mekhael
- Kristof Samoy
- Thibault Leneeuw
- Thomas Couvreur
- Wim Lewi
- Jacob Mekhael
Inventiva A MASH turnaround story with big upside potential
Inventiva's lanifibranor is the next in line candidate in MASH, with its phase 3 (NATiV3) trial now fully recruited, locking in a topline readout for 2H26. The program is de-risked by a robust phase 2b, showing competitive fibrosis response rates and strong HbA1c reduction— a key differentiator for the large MASH + T2D population. With oral dosing and clean safety, lanifibranor is well-positioned to capture a meaningful share of the validated MASH commercial opportunity. A € 348m structured fina...
Voting Rights and Shares Capital of the Company
Voting Rights and Shares Capital of the Company In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Market: Euronext Paris / NasdaqEuronext Compartment: B ISIN code: FR0011341205Nasdaq: NBTXBloomberg: NANO:FPReuters: NANO.PAWebsite: DateNumber of Shares OutstandingTotal number of voting rightsTotal voting rights, theoretical1Total voting rights,exercisable2July 31, 202548,236,67150,340,73650,318,618 About NANOBIOTIX ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.